Core Insights - Novo Nordisk's oral weight loss drug, semaglutide, has received FDA approval and will be marketed as Wegovy in the U.S., marking it as the first approved oral GLP-1 weight loss medication globally [1][2] - The approval led to a nearly 10% increase in Novo Nordisk's stock price, while competitor Eli Lilly's stock fell over 1% [1] - Analysts predict that oral weight loss medications could capture about 20% of the market by 2030, with Novo Nordisk currently leading in this segment [1] Product Details - The oral semaglutide contains 25 mg of the active ingredient, and a 64-week clinical study showed an average weight loss of 16.6% among participants, with over 34% achieving a weight reduction of 20% or more [2] - The drug is produced in North Carolina, ensuring sufficient supply, and previously, Novo Nordisk's oral semaglutide was only available for type 2 diabetes treatment [2] Market Dynamics - Novo Nordisk's market share has significantly declined this year, with stock prices dropping over 44%, raising investor concerns about the company's ability to recover amidst competition from Eli Lilly [2] - The patent for semaglutide in China will expire in 2026, leading to potential competition from generic drugs, making the global launch of the oral version crucial for regaining market share [2] Competitive Landscape - Novo Nordisk's oral semaglutide requires fasting before consumption, while Eli Lilly's upcoming oral drug, orforglipron, does not have such restrictions, which may affect consumer preference [3] - Goldman Sachs analysts estimate that the oral weight loss drug market could reach approximately $22 billion by 2030, with Eli Lilly's orforglipron expected to capture about 60% of this market, while Novo Nordisk's share could be around 21% [3]

Core Viewpoint - Novo Nordisk's oral GLP-1 drug, semaglutide, is expected to receive FDA approval for weight loss in the U.S. by the end of this year, while no oral GLP-1 drugs for weight loss are currently available globally [3][10]. Group 1: Market Situation - There is a significant presence of products labeled as "oral," "weight loss," and "semaglutide" on major e-commerce platforms in China, primarily sourced from Japan and shipped from Hong Kong [3][10]. - The most common products found include "semaglutide weight loss tablets" in 3mg and 7mg dosages, with prices such as 638 RMB for 20 tablets of 7mg and 1498 RMB for 100 tablets of 3mg [3][10]. - Following inquiries about the legality of these sales, all such products were removed from the platforms [9]. Group 2: Regulatory Compliance - Semaglutide is classified as a prescription drug and must be purchased with a prescription, indicating that the current sales channels are non-compliant [10]. - The approved indication for semaglutide oral tablets globally is for the treatment of type 2 diabetes, with no current approval for weight loss, including in Japan [10]. Group 3: Pricing and Availability - Many domestic patients seeking weight loss are reportedly purchasing semaglutide through proxy channels from Japan, where the pricing is notably lower [18]. - The lowest price for the 3mg oral semaglutide in Japan is approximately 139.6 JPY per tablet, equivalent to about 6.8 RMB [18]. - The oral semaglutide "Nuohexin" is expected to be approved for type 2 diabetes treatment in China in January 2024, and it will also require a prescription for purchase [18].

Core Viewpoint - The oral version of semaglutide, a GLP-1 drug by Novo Nordisk, is expected to receive FDA approval for weight loss in the U.S. by the end of this year, while currently, no oral GLP-1 drugs for weight loss are available globally, including Japan [1][6] Pricing and Market Availability - The price of oral semaglutide in Japan is among the lowest globally, with the 3 mg dosage priced at approximately 139.6 Japanese yen per piece, equivalent to about 6.8 RMB [9] - On a major e-commerce platform, the 7 mg dosage of oral semaglutide is priced at 638 RMB for 20 pieces, while the 3 mg dosage is priced at 1498 RMB for 100 pieces [1] Regulatory Compliance - Following inquiries about the legality of sales on e-commerce platforms, all related products were taken down, as semaglutide is a prescription drug that requires a prescription for purchase [6] - Currently, the approved indication for oral semaglutide globally is for the treatment of type 2 diabetes, with no approval for weight loss indications [6][9] Consumer Behavior - Many domestic patients seeking weight loss are reportedly purchasing oral semaglutide through proxy channels from Japan [9] - The oral version of semaglutide, branded as "Nuohexin," is expected to be approved for type 2 diabetes treatment in China in January 2024, and it will also require a prescription for purchase [9]